Changes in Hong Kong stocks | McPharmaceutical-B (02335) surged nearly 30% in the afternoon, and all enrolled participants completed the phase III clinical trial of MT1013

The Zhitong Finance App learned that McPharmaceutical-B (02335) soared by nearly 30% in the afternoon. As of press release, it rose 18.98% to HK$22.38, with a turnover of HK$154 million.

According to the news, McPharmaceuticals announced in the afternoon that in the critical phase III clinical trial of MT1013, the company's core product, all enrolled participants have completed the study, treatment and follow-up procedures stipulated in all trial plans, and have already left the team.

According to public information, MT1013, the core product of Maike Pharmaceutical, is the world's first dual-target receptor agonist polypeptide. It can simultaneously target CasR and OGP receptors. It is mainly used to treat hyperparathyroidism secondary to chronic kidney disease. It has now entered phase III clinical trials. In the head-to-head phase II clinical trial, MT1013 had a comprehensive compliance rate of iPTH, blood calcium, and blood phosphorus about 2.5 times higher compared with the approved drug etkapeptide, and was effective within three weeks.